Company
Open menu
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Open menu
Product Overview
AR-301 (Tosatoxumab)
AR-320 (Suvratoxumab)
AR-501 (Panaecin™)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin®)
AR-101 (Aerumab™)
AR-201
TECHNOLOGY
Open menu
Technology Overview
⅄PEX™
MabIgX®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Contact Us
Open menu
Contact Us
Careers
X
Search for:
Search Button
Company
Open menu
Company Overview
Board of Directors
Executive Team
Advisory Board
Pipeline
Open menu
Product Overview
AR-301 (Tosatoxumab)
AR-320 (Suvratoxumab)
AR-501 (Panaecin™)
AR-701 (COVID-19 mAb)
Preclinical
AR-401
Out-licensed Products
AR-105 (Aerucin®)
AR-101 (Aerumab™)
AR-201
TECHNOLOGY
Open menu
Technology Overview
⅄PEX™
MabIgX®
Therapeutic Targets
HAP / VAP
VAP Prevention
Cystic Fibrosis
COVID-19 Disease
Investors
Contact Us
Open menu
Contact Us
Careers
X
Search for:
Search Button
Investor Inquiries
Corporate Governance
Open menu
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Open menu
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor Alerts
Investor Inquiries
X
Corporate Governance
Open menu
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Open menu
Historical Stock Price
Analyst Coverage
Events and Webcasts
Publications and Posters
Investor Alerts
Investor Inquiries
X
Dave Gentry
Redchip Investor Relations
1-800-733-2447
Dave@redchip.com
